Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

63 results

Filters applied: . Clear all
Page 1
Comparison of Characteristics and Outcomes of Veterans With Stable Ischemic Heart Disease Enrolled in the COURAGE Trial Versus the Veterans Affairs Clinical Assessment, Reporting, and Tracking Program.
Smilowitz NR, Carey EP, Shah B, Hartigan PM, Plomondon ME, Maron DJ, Maddox TM, Spertus JA, Mancini GBJ, Chaitman BR, Weintraub WS, Sedlis SP, Boden WE; COURAGE Trial Investigators and VA CART CL. Smilowitz NR, et al. Among authors: chaitman br. Am J Cardiol. 2022 Oct 1;180:1-9. doi: 10.1016/j.amjcard.2022.06.049. Epub 2022 Jul 30. Am J Cardiol. 2022. PMID: 35918234 Free PMC article. Clinical Trial.
Patient-level comparisons were made between patients from VA CART who met the eligibility criteria for COURAGE and veterans enrolled in COURAGE between 1999 and 2004. All-cause mortality over long-term follow-up was assessed using Cox proportional hazards models. ...
Patient-level comparisons were made between patients from VA CART who met the eligibility criteria for COURAGE and veterans enrolled in COUR …
Myocardial Infarction in the ISCHEMIA Trial: Impact of Different Definitions on Incidence, Prognosis, and Treatment Comparisons.
Chaitman BR, Alexander KP, Cyr DD, Berger JS, Reynolds HR, Bangalore S, Boden WE, Lopes RD, Demkow M, Piero Perna G, Riezebos RK, McFalls EO, Banerjee S, Bagai A, Gosselin G, O'Brien SM, Rockhold FW, Waters DD, Thygesen KA, Stone GW, White HD, Maron DJ, Hochman JS; ISCHEMIA Research Group. Chaitman BR, et al. Circulation. 2021 Feb 23;143(8):790-804. doi: 10.1161/CIRCULATIONAHA.120.047987. Epub 2020 Dec 3. Circulation. 2021. PMID: 33267610 Free PMC article. Clinical Trial.
Influence of LDL-Cholesterol Lowering on Cardiovascular Outcomes in Patients With Diabetes Mellitus Undergoing Coronary Revascularization.
Farkouh ME, Godoy LC, Brooks MM, Mancini GBJ, Vlachos H, Bittner VA, Chaitman BR, Siami FS, Hartigan PM, Frye RL, Boden WE, Fuster V. Farkouh ME, et al. Among authors: chaitman br. J Am Coll Cardiol. 2020 Nov 10;76(19):2197-2207. doi: 10.1016/j.jacc.2020.09.536. J Am Coll Cardiol. 2020. PMID: 33153578 Free article.
CONCLUSIONS: In patients with coronary heart disease with T2DM, lower LDL-C at 1 year is associated with improved long-term MACCE outcome in those eligible for either PCI or CABG. When compared with optimal medical therapy alone, PCI was associated with MACCE reductions on …
CONCLUSIONS: In patients with coronary heart disease with T2DM, lower LDL-C at 1 year is associated with improved long-term MACCE out …
Effect of Coronary Anatomy and Myocardial Ischemia on Long-Term Survival in Patients with Stable Ischemic Heart Disease.
Weintraub WS, Hartigan PM, Mancini GBJ, Teo KK, Maron DJ, Spertus JA, Chaitman BR, Shaw LJ, Berman D, Boden WE. Weintraub WS, et al. Among authors: chaitman br. Circ Cardiovasc Qual Outcomes. 2019 Feb;12(2):e005079. doi: 10.1161/CIRCOUTCOMES.118.005079. Circ Cardiovasc Qual Outcomes. 2019. PMID: 30773025
Accordingly, we sought to clarify their association with long-term survival in the COURAGE trial (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation). ...Conclusions In univariate analysis, the number of coronary arteries diseased predicted long- …
Accordingly, we sought to clarify their association with long-term survival in the COURAGE trial (Clinical Outcomes Utilizing Revascu …
SYNTAX Score and Long-Term Outcomes: The BARI-2D Trial.
Ikeno F, Brooks MM, Nakagawa K, Kim MK, Kaneda H, Mitsutake Y, Vlachos HA, Schwartz L, Frye RL, Kelsey SF, Waseda K, Hlatky MA; BARI-2D Study Group. Ikeno F, et al. J Am Coll Cardiol. 2017 Jan 31;69(4):395-403. doi: 10.1016/j.jacc.2016.10.067. J Am Coll Cardiol. 2017. PMID: 28126156 Free article.
Medical Treatment and Revascularization Options in Patients With Type 2 Diabetes and Coronary Disease.
Mancini GB, Farkouh ME, Brooks MM, Chaitman BR, Boden WE, Vlachos H, Hartigan PM, Siami FS, Sidhu MS, Bittner V, Frye R, Fuster V. Mancini GB, et al. Among authors: chaitman br. J Am Coll Cardiol. 2016 Sep 6;68(10):985-95. doi: 10.1016/j.jacc.2016.06.021. J Am Coll Cardiol. 2016. PMID: 27585501 Free article.
OBJECTIVES: This study determined the effect of optimal medical therapy (OMT), with or without percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG), on long-term outcomes with respect to LVEF and number of diseased vessels, including proximal …
OBJECTIVES: This study determined the effect of optimal medical therapy (OMT), with or without percutaneous coronary intervention (PCI) or c …
Effect of PCI on Long-Term Survival in Patients with Stable Ischemic Heart Disease.
Sedlis SP, Hartigan PM, Teo KK, Maron DJ, Spertus JA, Mancini GB, Kostuk W, Chaitman BR, Berman D, Lorin JD, Dada M, Weintraub WS, Boden WE; COURAGE Trial Investigators. Sedlis SP, et al. Among authors: chaitman br. N Engl J Med. 2015 Nov 12;373(20):1937-46. doi: 10.1056/NEJMoa1505532. N Engl J Med. 2015. PMID: 26559572 Free PMC article. Clinical Trial.
Effect of baseline exercise capacity on outcomes in patients with stable coronary heart disease (a post hoc analysis of the clinical outcomes utilizing revascularization and aggressive drug evaluation trial).
Padala SK, Sidhu MS, Hartigan PM, Maron DJ, Teo KK, Spertus JA, Mancini GB, Sedlis SP, Chaitman BR, Heller GV, Weintraub WS, Boden WE. Padala SK, et al. Among authors: chaitman br. Am J Cardiol. 2015 Nov 15;116(10):1509-15. doi: 10.1016/j.amjcard.2015.08.012. Epub 2015 Aug 31. Am J Cardiol. 2015. PMID: 26410604 Free PMC article. Clinical Trial.
There was no statistically significant interaction between the original treatment arm allocation (PCI + OMT vs OMT) and baseline exercise capacity. In conclusion, there was no difference in the long-term clinical outcomes in patients with exercise capacity <7 METs compa …
There was no statistically significant interaction between the original treatment arm allocation (PCI + OMT vs OMT) and baseline exercise ca …
Liberal versus restrictive blood transfusion strategy: 3-year survival and cause of death results from the FOCUS randomised controlled trial.
Carson JL, Sieber F, Cook DR, Hoover DR, Noveck H, Chaitman BR, Fleisher L, Beaupre L, Macaulay W, Rhoads GG, Paris B, Zagorin A, Sanders DW, Zakriya KJ, Magaziner J. Carson JL, et al. Among authors: chaitman br. Lancet. 2015 Mar 28;385(9974):1183-9. doi: 10.1016/S0140-6736(14)62286-8. Epub 2014 Dec 9. Lancet. 2015. PMID: 25499165 Free PMC article. Clinical Trial.
Long-term mortality was established by linking the study participants to national death registries in the USA and Canada. ...These findings do not support hypotheses that blood transfusion leads to long-term immunosuppression that is severe enough to affect long- …
Long-term mortality was established by linking the study participants to national death registries in the USA and Canada. ...These fi …
Effect of ranolazine on atrial fibrillation in patients with non-ST elevation acute coronary syndromes: observations from the MERLIN-TIMI 36 trial.
Scirica BM, Belardinelli L, Chaitman BR, Waks JW, Volo S, Karwatowska-Prokopczuk E, Murphy SA, Cheng ML, Braunwald E, Morrow DA. Scirica BM, et al. Among authors: chaitman br. Europace. 2015 Jan;17(1):32-7. doi: 10.1093/europace/euu217. Epub 2014 Sep 10. Europace. 2015. PMID: 25210025 Clinical Trial.
AIMS: To determine the effect of ranolazine, an anti-ischaemic agent with anti-arrhythmic properties, on the overall burden of atrial fibrillation (AF) in acute coronary syndromes (ACS) and determine whether ranolazine reduces the long-term incidence of clinical AF after A …
AIMS: To determine the effect of ranolazine, an anti-ischaemic agent with anti-arrhythmic properties, on the overall burden of atrial fibril …
63 results